Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A071401||Alliance||Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations||Adult CIRB - Early Phase Emphasis||Available to Open|
|A021502||Alliance||Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC*)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041703||Alliance||Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|A231602CD||Alliance||Assessing Financial Difficulty in Patients with Blood Cancers||Cancer Prevention and Control CIRB||Available to Open|
|A191402CD||Alliance||Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men||Cancer Prevention and Control CIRB||Available to Open|
|A071601||Alliance||Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|A081105||Alliance||Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031102||Alliance||A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel; Ifosfamide; and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041501||Alliance||A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221208||Alliance||Randomized Phase II Study: Corticosteroids and Bevacizumab vs. Corticosteroids and Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases||Cancer Prevention and Control CIRB||Available to Open|